Privia Health Group, Inc. PRVA

Healthcare SIC 8000 - Services-Health Services NAICS Health Care and Social Assistance derived Nasdaq

Privia Health Group, Inc. ("Privia Health", "we", "our", or the "Company") is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. We seek to accomplish the quadruple aim by entering markets and organizing existing physicians and non-physician clinicians into a unique practice model that combines the advantages of a partnership in a large regional medical group (each, a "Medical Group") with significant provider autonomy for the physicians (collectively, "Privia Physicians") and non-physician clinicians (collectively "Privia Clinicians" and, together with the Privia Physicians, the "Privia Providers") in our Medical Groups.

Last close 22.41 2026-10-23
Market cap $2.86B 2026-06-30 share count
52-week range 18.91 - 28.82

Valuation FY2025 figures against the last close

P/S1.3x
P/E124.5x
P/FCF17.5x
EV/EBITDA64.8x
Dividend yield—
Diluted EPS0.18

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $2.12B$1.74B$1.66B$1.36B$966.2M$817.1M$786.4M—
SG&A $138.2M$126.2M$109.6M$129.6M$255.9M$44.0M$41.8M—
Total operating expenses $2.09B$1.72B$1.64B$1.38B$1.18B$791.7M$770.3M—
Operating income $34.2M$17.0M$20.6M-$19.1M-$217.4M$25.4M$16.1M—
Interest expense ——$8.4M$542.0K$1.1M$1.9M$4.0M—
Pre-tax income $43.9M$27.9M$29.0M-$18.6M-$218.5M$23.5M$9.2M—
Income tax $14.2M$10.8M$8.0M$6.5M$27.9M$7.4M$1.2M—
Net income $22.9M$14.4M$23.1M-$8.6M-$188.2M$31.2M$8.2M—
EPS, basic 0.190.120.20-0.08-1.830.330.09—
EPS, diluted 0.180.110.19-0.08-1.830.330.09—
Shares, diluted (wtd. avg.) 128.9M125.6M124.7M110.7M103.0M96.0M95.9M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $479.7M$491.1M$389.5M$348.0M$320.6M$84.6M$46.9M$39.1M
Receivables $400.9M$316.2M$290.8M$189.6M$117.4M$99.1M——
Total current assets $911.0M$834.8M$700.8M$552.0M$446.7M$190.1M——
Property, plant and equipment $504.0K$1.2M$2.3M$3.4M$4.5M$4.8M——
Goodwill $209.8M$141.6M$138.7M$126.9M$127.9M$118.7M——
Other intangibles $215.9M$109.8M$107.6M$57.4M$59.7M$6.0M——
Total assets $1.37B$1.14B$999.9M$792.8M$686.4M$329.0M——
Accounts payable $8.0M$9.8M$7.9M$6.7M$3.0M$5.2M——
Total current liabilities $568.5M$449.1M$387.0M$264.3M$190.5M$146.9M——
Total liabilities $578.4M$452.3M$392.5M$273.8M$236.2M$185.3M——
Retained earnings -$156.3M-$179.2M-$193.6M-$216.7M-$208.1M-$19.9M——
Total equity $737.2M$635.2M$607.4M$519.0M$450.2M$143.7M$107.5M$86.0M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $163.4M$109.3M$80.8M$47.2M$55.1M$38.9M$24.4M—
Depreciation and amortisation $9.9M$7.3M$6.5M$4.6M$2.5M$1.8M$1.4M—
Stock-based compensation $71.1M$56.7M$37.1M$67.4M$253.5M$484.0K$207.0K—
Capital expenditure ——$113.0K$104.0K$547.0K$380.0K$5.7M—
Investing cash flow -$181.6M-$12.0M-$43.0M-$104.0K-$32.8M-$380.0K-$5.7M—
Financing cash flow $6.7M$4.3M$3.7M-$19.7M$213.7M-$767.0K-$10.9M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001759655-26-000010.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -1B 0 1B 2B 3B Revenue, FY2019: 786.4M Net income, FY2019: 8.2M Revenue, FY2020: 817.1M Net income, FY2020: 31.2M Revenue, FY2021: 966.2M Net income, FY2021: -188.2M Revenue, FY2022: 1.4B Net income, FY2022: -8.6M Revenue, FY2023: 1.7B Net income, FY2023: 23.1M Revenue, FY2024: 1.7B Net income, FY2024: 14.4M Revenue, FY2025: 2.1B Net income, FY2025: 22.9M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $786.4M $817.1M $966.2M $1.36B $1.66B $1.74B $2.12B
Gross profit — — — — — — — —
Net income — $8.2M $31.2M -$188.2M -$8.6M $23.1M $14.4M $22.9M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Other event Item 8.01
  • Other event Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8000

TickerCompanyMarket capP/ERevenue growth
LFST LifeStance Health Group, Inc. $4.94B — 13.9%
WGS GeneDx Holdings Corp. $1.67B — 40.0%
PNTG Pennant Group, Inc. $1.46B 49.9x 36.3%
USPH U S PHYSICAL THERAPY INC /NV $1.32B 62.3x 16.3%
INNV InnovAge Holding Corp. $1.30B — 11.8%
OMDA Omada Health, Inc. $1.16B — 53.2%
SRTA Strata Critical Medical, Inc. $412.3M 9.3x 34.3%
DCGO DocGo Inc. $26.8M — -47.7%